Meeting Coverage:

EURETINA Congress

EURETINA: 2020

RGX-314 for Wet AMD

Show Description +

Robert L. Avery, MD, shares data from a phase 1/2a study that evaluated the safety and efficacy of RGX-314 (RegenxBio) for the treatment of wet AMD. Dr. Avery provides an update on the most recent readouts of the trial and previews forthcoming trials in wet AMD and diabetic retinopathy.

Posted: 10/05/2020

RGX-314 for Wet AMD

Robert L. Avery, MD, shares data from a phase 1/2a study that evaluated the safety and efficacy of RGX-314 (RegenxBio) for the treatment of wet AMD. Dr. Avery provides an update on the most recent readouts of the trial and previews forthcoming trials in wet AMD and diabetic retinopathy.

Posted: 10/05/2020


Please log in to leave a comment.